Objective Response Rate Among Patients With Locally Advanced or Metastatic Sarcoma Treated With Talimogene Laherparepvec in Combination With Pembrolizumab: A Phase 2 Clinical Trial

IMPORTANCE: Patients with advanced sarcoma have limited treatment options. Talimogene laherparepvec (T-VEC) has been shown to increase tumor-specific immune activation via augmenting antigen presentation and T-cell priming. OBJECTIVE: To examine whether T-VEC in combination with pembrolizumab is ass...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:JAMA Oncol
Autors principals: Kelly, Ciara M., Antonescu, Cristina R., Bowler, Timothy, Munhoz, Rodrigo, Chi, Ping, Dickson, Mark A., Gounder, Mrinal M., Keohan, Mary Louise, Movva, Sujana, Dholakia, Reena, Ahmad, Hamza, Biniakewitz, Matthew, Condy, Mercedes, Phelan, Haley, Callahan, Margaret, Wong, Phillip, Singer, Sam, Ariyan, Charlotte, Bartlett, Edmund K., Crago, Aimee, Yoon, Sam, Hwang, Sinchun, Erinjeri, Joseph P., Qin, Li-Xuan, Tap, William D., D’Angelo, Sandra P.
Format: Artigo
Idioma:Inglês
Publicat: American Medical Association 2020
Matèries:
Original Investigation
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6990941/
https://ncbi.nlm.nih.gov/pubmed/31971541
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2019.6152
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars